Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2163564 | 0.90 | L3MBTL1 (0.51) | L3MBTL1MAPK1BRD4USP2GAA | |
| SCHEMBL8117465 | 0.86 | L3MBTL1 (0.48) | L3MBTL1MAPK1BRD4USP2GAA | |
| SCHEMBL532921 | 0.84 | USP2 (0.48) | L3MBTL1MAPK1USP2GAATSHR | |
| SCHEMBL10505826 | 0.82 | L3MBTL1 (0.55) | L3MBTL1MAPK1BRD4USP2GAA | |
| SCHEMBL5670684 | 0.79 | HSD17B10 (0.53) | MAPK1BRD4USP2GAATSHR | |
| SCHEMBL5188341 | 0.74 | PARP1 (0.57) | BRD4USP2GAAHSD17B10 | |
| SCHEMBL532347 | 0.74 | PARP1 (0.57) | BRD4USP2GAAHSD17B10 | |
| SCHEMBL5342897 | 0.74 | PARP1 (0.57) | BRD4USP2GAAHSD17B10 | |
| SCHEMBL5670690 | 0.73 | PARP1 (0.55) | MAPK1BRD4USP2GAATSHR | |
| SCHEMBL10506118 | 0.73 | BRD4 (0.44) | L3MBTL1MAPK1BRD4USP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534676-B1 | PIPERIDINETRIOL DERIVATIVES AS INHIBITORS OF GLYCOSYLCERAMIDE SYNTHASE | ACTELION PHARMACEUTICALS LTD (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-7985760-B2 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-07-26 | — | — | US | disclosed |
| US-20060058349-A1 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | OXFORD GLYCOSCIENCES(UK) LTD (GB) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058349-A1 | Piperidinetriol derivatives as inhibitors of glycosyceramid synthase | CERS2, UGCG, GBA1 | L3MBTL1 4396/4885MAPK1 3069/4885BRD4 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.